Sign in
SuspendedPhase 2

The Dose Finding Study of DAOIB Added to tDCS for AD

Key facts

Who runs it
Chang Gung Memorial Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 2
People taking part
140 people, planned
Starts
Jan 2027
Expected to end
Dec 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • DAOIB
Record updated
20 March 2026
Why it stopped
The trial was suspended due to the budget issue

Who can take part

Age
50 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
  • MMSE between 10-26
  • CDR 1 or 0.5

Who cannot take part

  • Parkinson disease, epilepsy, dementia with psychotic features
  • Major depressive disorder
  • Major physical illnesses
  • Severe visual or hearing impairment
  • Hachinski Ischemic Score > 4
  • Substance abuse/dependence

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10 sessions in total) during the first 2 weeks of the study, and will also be allocated randomly to either of 4 treatment groups for 24 weeks: (1) Dose A group; (2) Dose B group; (3) Dose C group; (4) placebo group. We will assess the patients every 8 weeks during the treatment period (weeks 0, 10, 18, and 26). We hypothesize that augmentation with certain dose of DAOIB will yield better effect than tDCS alone in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.

The 4 groups in the trial

  • tDCS+Dose ATreatment being tested

    Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS

    Treatment: DAOIB

  • tDCS+Dose BTreatment being tested

    Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS

    Treatment: DAOIB

  • tDCS+Dose CTreatment being tested

    Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS

    Treatment: DAOIB

  • tDCS+placeboPlacebo, for comparison

    Drug: Placebo Placebo Device: tDCS tDCS

    Treatment: DAOIB

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Dose Finding Study of Sodium Benzoate Added to tDCS for the Treatment of Early-phase Alzheimer's Disease
Record updated
20 March 2026